Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma

Oncology Letters

Volumn 2, Issue 1, 2011, Pages 59-63

  Feng, Lu ^a   Li, Mei ^a   Zhang, Qiu Ping ^a   Piao, Zheng Ai ^b   Wang, Zhao Hui ^a   Lv, Shen ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Third People's Hospital of Dalian   (China)

Author keywords

hMSH2; Immunohistochemistry; Papillary thyroid carcinoma; Proliferating cell nuclear antigen; V raf murine sarcoma viral oncogene homolog B1

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CYCLINE; PROTEIN MSH2;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NODULAR GOITER; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA;

EID: 78751532625     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.219     Document Type: Article

References (18)

1. Mai KT, Perkins DG, Yazdi HM, Commons AS, Thomas J and Meban S: Infiltrating papillary thyroid carcinoma: review of 134 cases of papillary carcinoma. Arch Pathol Lab Med 122: 166-171, 1998.
2. Michaloglou C, Vredeveld LC, Mooi WJ and Peeper DS: BRAF (E600) in benign and malignant human tumours. Oncogene 27: 877-895, 2008.
3. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627, 2003.
4. Dhomen N and Marais R: New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31-39, 2007.
5. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246: 466-470, 2007.
6. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC and Cheng JT: No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol 63: 461-466, 2005.
7. Ito Y, Yoshida H, Maruo R, et al: BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56: 89-97, 2009.
8. Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P and Hofman P: Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem 17: 1839-1850, 2010.
9. Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL and Katoh R: Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol 38: 1810-1818, 2007.
10. Baserga R: Growth regulation of the PCNA gene. J Cell Sci 98: 433-436, 1991.
11. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S, Dalla Palma P and Barbareschi M: PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 45: 416-419, 1992.
12. El-kott AF, El-baz MA and Mokhtar AA: Proliferating cell nuclear antigen (PCNA) overexpression and microvessel density predict survival in the urinary bladder carcinoma. Int Urol Nephrol 38: 237-242, 2006.
13. Cvejic D, Selemetjev S, Savin S, Paunovic I and Tatic S: Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours. Eur J Histochem53: 65-71, 2009.
14. Jun SH, Kim TG and Ban C: DNA mismatch repair system. Classical and fresh roles. FEBS J 273: 1609-1619, 2006.
15. Plevová P, Krepelová A, Papezová M, et al: Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer. Neoplasma 51: 275-284, 2004.
16. Li M, Liu L, Wang Z, Wang L, Liu Z, Xu G and Lu S: Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep 19: 401-406, 2008.
17. Ciampi R, Zhu Z and Nikiforov YE: BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol 16: 99-105, 2005.
18. Wang L, Cunningham JM, Winters JL, Guenther JC, FrenchAJ, Boardman LA, Burgart LJ, McDonnell SK, Schaid DJ and Thibodeau SN: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63: 5209-5212, 2003.